Linden Capital Partners has promoted Michael Farah to partner and Kam Shah to principal. Also, the healthcare private equity firm has hired Michael Bernard and Max Gaby as vice presidents. Farah joined Linden in 2014 while Shah came on board in 2009. And, previously, Bernard worked at 3i Group and Gaby was at GTCR.
Chicago, Illinois (October 24, 2016) – Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, announced today the promotions of Michael Farah to Partner and Kam Shah to Principal, and Michael Bernard and Max Gaby joining as Vice Presidents.
“Our team has prevailed in partnering with premier businesses by following our disciplined approach of focusing on key healthcare sectors and integrating the expertise of operating executives and investment professionals,” commented Linden President and Managing Partner Tony Davis. “On behalf of the partnership, we are thrilled to recognize the performance of the team and welcome our newest teammates as we successfully execute the Linden strategy.” So far this year, Linden has consummated three platform investments, three portfolio add-on acquisitions, sold Corpak MedSystems to Halyard Health, and completed dividend recapitalizations at Young Innovations and Spear Education.
Michael Farah, who joined Linden in 2014, has been active on the pharmaceutical services and contract manufacturing sector teams, which led to investments in Flexan Corporation and ProPharma Group. Michael serves on the boards of Flexan, ProPharma Group, and Young Innovations and served on the board of Corpak MedSystems until its sale earlier this year. Michael started his career in the healthcare investment banking group at UBS, spent three years as a private equity associate with Summit Partners, followed by six years at Metalmark Capital focused on healthcare investing. He holds a Bachelor of Science in Business Administration, with Honors, from Carnegie Mellon University and an MBA from Harvard Business School.
Kam Shah joined Linden in 2009 as an associate and returned as a vice president in 2013 after completing business school. Kam serves on the board of Chesapeake IRB and is active on the pharmaceutical services and distribution sector teams. Prior to Linden, Kam was a private equity associate at Sun Capital Partners, Inc. He began his career as an investment banking analyst at Goldman, Sachs, where he focused on M&A advisory, capital raising, and leveraged buyout transactions. Kam holds a Bachelor of Science in Finance with high honors from the University of Illinois at Urbana-Champaign and an MBA from the Stanford Graduate School of Business.
Michael Bernard has been involved in principal investing and investment banking since 2007. He joins Linden from 3i Group where he spent the last two years focused on healthcare investing. He started his career at Morgan Stanley in the leveraged loan investment group before joining the healthcare investment banking group. Michael holds a Bachelor of Arts in Economics from Brown University and an MBA in Health Enterprise Management from the Kellogg School of Management.
Max Gaby has been involved in principal investing and investment banking since 2010. Prior to Linden, Mr. Gaby served as a private equity associate with GTCR and began his career as an investment banking analyst at Bank of America Merrill Lynch. Mr. Gaby holds a Bachelor of Science, cum laude, in Finance and International Studies from Georgetown University and an MBA from The University of Chicago Booth School of Business.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: (i) healthcare and life science industry specialization, (ii) integrated private equity and operating expertise, and (iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit